Monte Rosa Therapeutics(GLUE)
Focus: Monte Rosa is a Boston-based public biotech founded in 2024 specializing in small molecule cancer drugs that modulate protein degradation pathways (PROTAC technology). The company is early-stage with three clinical programs and recently completed a public offering (ticker: GLUE).
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
23+28 this month
Hot — 32 jobs added in 30d
Net +28 (32 new, 4 removed). Aggressive expansion phase.
Should You Work at Monte Rosa Therapeutics?
AI assessmentIdeal for scientists and clinicians seeking high-risk/high-reward opportunity in emerging technology with near-term upside; less suitable for those prioritizing stability, mentorship depth, or near-term career acceleration.
Why Work Here
- Platform technology with high R&D intensity (161%) signals deep investment in science and differentiation — you'll work on cutting-edge protein degradation mechanisms
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$76M
Pipeline & Clinical Trials
MRT-6160
Healthy VolunteersClinical Trials (1)
NCT06597799First-in-human Study of MRT-6160 in Healthy Subjects
Phase 1Help build intelligence for Monte Rosa Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.